July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure
Author Affiliations & Notes
  • tao guo
    Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
  • yuchen fan
    Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
  • li guo
    Department of Ophthalmology, Luan Affiliated Hospital of Anhui Medicine University, China
  • jiahong wei
    Department of Ophthalmology, Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
  • Footnotes
    Commercial Relationships   tao guo, None; yuchen fan, None; li guo, None; jiahong wei, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5154. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      tao guo, yuchen fan, li guo, jiahong wei; Effects of Salidroside on Trabecular Meshwork Cell Extracellular Matrix Expression and Mouse Intraocular Pressure. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5154.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Excessive accumulation of extracellular matrix (ECM) in the trabecular meshwork (TM) reduces aqueous humor outflow, which likely contributes to elevation of intraocular pressure (IOP) in primary open-angle glaucoma (POAG). Salidroside, a phenolic glycoside isolated from R. rosea is reported to prevent pro-fibrotic responses by inhibiting Smad signaling pathway activated by TGFβ in liver, lung, and kidney tissues. We tested if salidroside can (1) inhibit TGFβ2-induced ECM expression in cultured human TM cells, and (2) lower TGFβ2-induced ocular hypertension in the mouse.

Methods : Cultured human TM cells stimulated with 5 ng/mL TGFβ2 for 48 h were treated with salidroside for 24 h. The expressions of fibronectin (FN), collagen type IV (COL-IV), laminin (LN) were evaluated by quantitative PCR, western blot, and immunocytochemistry. BALB/cJ mice were injected intravitreally with an adenoviral vector encoding a bioactive mutant of TGFβ2 (Ad.hTGFβ2226/228) in one eye to induce ocular hypertension, with the uninjected contralateral or Ad.Empty-injected eyes serving as controls. Mice were treated with a daily intraperitoneal injection of 40 mg/kg salidroside. Conscious mouse IOP values were measured using a TonoLab rebound tonometer.

Results : In cultured human TM cells, treatment with TGFβ2 increased expressions of FN, COL-IV, and LN, as assessed by qPCR, western blot, and immunocytochemistry, all of which were significantly and completely ameliorated by 30 μM salidroside. Daily intraperitoneal injections of salidroside (40 mg/kg), starting either at Day 0 (same day as Ad.hTGFβ2226/228 injection) or at Day 14, significantly lowered TGFβ2-induced ocular hypertension in the mouse. In contrast, salidroside did not affect IOP of control eyes.

Conclusions : These results demonstrated that salidroside is capable of minimizing TGFβ2-induced ECM expression in cultured human TM cells. It also reduced TGFβ2-induced ocular hypertension in the mouse. These findings indicate that this phenolic glycoside may be useful as a novel treatment for POAG.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×